New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 14, 2014
07:36 EDTENZYEnzymotec sees FY14 EPS 64c-94c, consensus 86c
Sees FY14 revenue, based on the proportionate consolidation method, $90M-$110M, consensus $92.95M. Sees FY14 revenue, based on the equity method, $68M-$85M.
News For ENZY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 13, 2014
07:39 EDTENZYEnzymotec sees FY14 EPS 36c-45c, consensus 36c
Sees FY14 revenue $47M-$50M, consensus $48.5M.
07:37 EDTENZYEnzymotec reports Q3 EPS 5c, consensus 4c
Subscribe for More Information
November 11, 2014
08:41 EDTENZYEnzymotec initiates clinical study of Vayarin
Enzymotec announced the initiation of a clinical study to evaluate the efficacy of Vayarin in adults with Attention Deficit Hyperactivity Disorder, or ADHD. The randomized, double-blind, placebo-controlled study will enroll 171 patients between the ages of eighteen and fifty-five. This will be a multi-center study in the United States, including the NYU School of Medicine. The study was designed to assess the efficacy of Vayarin in adults with ADHD, measured primarily by the ADHD Investigator Symptom Rating Scale.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use